Evidence map›Paper›PMID 37458281›Full record

ReviewHematological oncology2024

Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia.

Karima Amaador, Catherine Thieblemont, Judith Trotman, Monique C Minnema

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hematological oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Karima AmaadorDepartment of Internal Medicine, UMC Utrecht, Utrecht, The Netherlands.
Catherine ThieblemontUniversité Paris Cité, Assistance Publique & Hôpitaux de Paris, Paris, France.
Judith TrotmanDepartment of Haematology, Concord Repatriation General Hospital and Faculty of Medicine and Health, University of Sydney, Concord, New South Wales, Australia.ORCID https://orcid.org/0000-0001-8009-4593
Monique C MinnemaDepartment of Hematology, UMC Utrecht, University Utrecht, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0002-3139-8379

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Marginal Zone Lymphoma (MZL) and Waldenström's Macroglobulinemia (WM) are indolent lymphomas that both arise from post germinal center lymphocytes. Both can secrete a monoclonal protein but high levels are mostly only seen in WM. The MYD88 L256P somatic mutation that is present in an estimated 95% of patients with WM has helped greatly in differentiating the two lymphomas. Several large clinical studies with new drugs have been performed that have provided new treatment options for both MZL and WM patients. In this short review we will discuss the recent literature published and provide some recommendations.

Indexed as

Lymphoma, B-Cell, Marginal ZoneWaldenstrom MacroglobulinemiaHumansMutationMyeloid Differentiation Factor 88MYD88 protein, humanMyeloid Differentiation Factor 88marginal zone lymphomatreatmentWaldenstrom macroglobulinemia

Identifiers

PMID37458281
PMCPMC11590047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.